NCT03839446 2025-02-20
Phase II Study of the Combination of Mitoxantrone, Etoposide and Gemtuzumab Ozogamicin (MEGO) for Patients With Acute Myeloid Leukemia Refractory to Initial Standard Induction Therapy
University of Pittsburgh
Phase 2 Completed
Clinical Trials
19 trialsNCT02117297 2023-10-26
SCT Plus Immune Therapy in Average Risk AML/MDS
New York Medical College
Phase 2 Completed
NCT02221310 2023-10-26
Immunochemotherapy and AlloSCT in Patients With High Risk CD33+ AML/MDS
New York Medical College
Phase 2 Completed
NCT00005962 2023-06-22
Comparison of Three Treatment Regimens in Treating Patients With Relapsed or Refractory Acute Myelogenous Leukemia
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT04173585 2023-03-27
TEAM
University Hospital Heidelberg
Phase 2 Completed
NCT00551460 2023-01-10
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia
SWOG Cancer Research Network
Phase 2 Completed
NCT00070174 2014-02-20
Gemtuzumab Ozogamicin in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Undergoing Remission Induction and Intensification Therapy
Children's Oncology Group
Phase 2 Completed
NCT00017589 2014-01-06
Oblimersen and Gemtuzumab Ozogamicin in Treating Older Patients With Relapsed Acute Myeloid Leukemia
National Cancer Institute (NCI)
Phase 2 Completed
NCT00882102 2013-09-13
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia (AML) and High-Risk Myelodysplastic Syndrome (H-R MDS)
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00195000 2013-06-19
Mylotarg and Ara-C in Untreated Patients Above 60 Years With AML and High-Risk MDS
Weill Medical College of Cornell University
Phase 2 Completed
NCT00968071 2013-03-08
Decitabine and Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia and High-risk Myelodysplastic Syndrome
M.D. Anderson Cancer Center
Phase 2 Completed
NCT00037596 2013-02-13
Study Evaluating Gemtuzumab Ozogamicin in Acute Myeloid Leukemia
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 2 Completed
NCT00003673 2012-08-22
CMA-676 in Treating Older Patients With Acute Myeloid Leukemia in First Relapse
Pfizer
Phase 2 Completed
NCT00006122 2012-07-16
Gemtuzumab Ozogamicin With or Without Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia
European Organisation for Research and Treatment of Cancer - EORTC
Phase 2 Completed
NCT00089050 2011-11-30
Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00143975 2010-08-12
Gemtuzumab Ozogamicin in Combination With A-HAM in Refractory AML (GO-A-HAM)
University of Ulm
Phase 2 Completed
NCT00008151 2010-04-02
Gemtuzumab Ozogamicin, Fludarabine, and Total-body Irradiation Followed by Peripheral Stem Cell or Bone Marrow Transplantation in Treating Patients With Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome
Fred Hutchinson Cancer Center
Phase 2 Completed
NCT00037583 2009-08-21
Study Evaluating the Safety and Efficacy of Gemtuzumab Ozogamicin in Patients With Acute Myeloid Leukemia
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 2 Completed
NCT00044733 2006-05-18
Study Evaluating Gemtuzumab Ozogamicin in Acute Myelogenous Leukemia After Stem Cell Transplant
Wyeth is now a wholly owned subsidiary of Pfizer
Phase 2 Completed